SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (5349)2/8/1998 11:36:00 PM
From: Bradpalm1  Read Replies (1) | Respond to of 23519
 
Tunica,

Three things concern me about Vivus in the short-term:

1). European rollout less than spectacular

2). Production ramp-up not to take place until Q2 at the earliest

3). FDA approval of Viagra to be announced within a month (bypassed FDA review committee)

Why do you think the shorts haven't covered yet, Tuna.

Bradpalm1



To: Tunica Albuginea who wrote (5349)2/9/1998 7:58:00 PM
From: LoLoLoLita  Respond to of 23519
 
>>MUSE, 1000 mg

TA,

you probably mean micrograms (mcg), not milligrams. but hey, if
you write me a scrip for Valium in kg, I'll be happy!

Still Long VVUS!

Cheers,

David


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News